Researcher: Dr. Cheryl A. London, DVM PhD; Ohio State University
Program Area: Treatment
Sponsor(s): .
Project Dates: 4/1/2008 to 3/31/2010
Grant Amount: $34,363.00
DCAF Funding: $2,500.00.
Abstract:
-
- Dr. London’s research team has been investigating the production of inflammatory mediators (also known as eicosanoids) by canine mast cells that contribute to a variety of diseases such as atopy and arthritis. The purpose of their work is to determine if currently available non-steroidal antiinflammatory drugs (NSAIDs) such as Rimadyl and Zubrin (among others) are capable of modifying their production. The use of NSAIDs would be an attractive alternative to the use of corticosteroids to modulate mast cell function. The preliminary data indicate that Zubrin is very effective at blocking the production of mast cell derived eicosanoids when mast cells are exposed to standard doses of drug. Therefore, results from these studies may provide a new strategy to modify the function of mast cells in several inflammatory disorders.